WO2016074203A1 - Inducteur d'apoptose cellulaire contenant du dioxyde de chlore et son utilisation pour préparer des produits cosmétiques ou des médicaments anti-vieillissement ou anti-néoplasiques - Google Patents

Inducteur d'apoptose cellulaire contenant du dioxyde de chlore et son utilisation pour préparer des produits cosmétiques ou des médicaments anti-vieillissement ou anti-néoplasiques Download PDF

Info

Publication number
WO2016074203A1
WO2016074203A1 PCT/CN2014/091047 CN2014091047W WO2016074203A1 WO 2016074203 A1 WO2016074203 A1 WO 2016074203A1 CN 2014091047 W CN2014091047 W CN 2014091047W WO 2016074203 A1 WO2016074203 A1 WO 2016074203A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
cancer
chlorine dioxide
cells
apoptosis
Prior art date
Application number
PCT/CN2014/091047
Other languages
English (en)
Chinese (zh)
Inventor
刘学武
Original Assignee
刘学武
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 刘学武 filed Critical 刘学武
Priority to PCT/CN2014/091047 priority Critical patent/WO2016074203A1/fr
Publication of WO2016074203A1 publication Critical patent/WO2016074203A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/20—Halogens; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • Another object of the present invention is to provide an application of chlorine dioxide in the preparation of a medicament for use in a mammalian apoptosis inducing agent.
  • a drug for promoting apoptosis of a tumor cell in a mammal has an apoptosis inducer containing chlorine dioxide, and the drug can specifically induce apoptosis of the tumor cell to achieve better tumor treatment effect. With little side effects or no side effects, the burden on patients is lighter.
  • the present invention also provides the use of chlorine dioxide for the preparation of a medicament for inducing apoptosis in a mammal, wherein the medicament is for treating cancer, in particular for inducing tumor cell apoptosis in a mammal.
  • the chlorine dioxide of the present invention is used in the preparation of a medicament for inducing apoptosis in a mammal, the medicament of which may be administered at risk of developing cancer, diagnosed with cancer, during cancer treatment or at The individual of the subject during recovery from cancer treatment, or the drug can be administered as a prophylactic to the individual of the subject to prevent or delay the progression of the cancer.
  • apoptotic cells are more likely to die under acidic conditions. Apoptotic cells have enhanced glycolysis and increased acidic metabolites. If externally applied acid pressure (lower pH), apoptotic cells will accelerate toward death. For example, cardiac hypertrophy is a defensive response of myocardial tissue to increased load to temporarily adapt to changes in overall or local myocardial stress. If the need for cardiac physiology exceeds the compensatory capacity of cardiomyocytes, suicide death occurs in cardiomyocytes. That is, apoptosis is one of the main mechanisms for the conversion of cardiac hypertrophy to heart failure.
  • the tumor cells excrete hydrogen ions outward, eventually producing an extracellular acidic environment and an alkaline environment inside the cells.
  • Tumor cells regulate hydrogen ion-associated transporters of the plasma membrane, such as sodium-hydrogen exchange protein (Na + /H + ), Na + /K + -ATPase, vesicular H + -ATPases, H + /CI - co-transporters And monocarboxylic acid transporter (MCT), etc., to achieve this mechanism (Harguindey S, et al. The role of pH dynamics and the Na+/H+antiporter in the etiopathogenesis and treatment of cancer. Two faces of the same coin- -one single nature, [J]. Biochim BiopHys Acta, 2005, 1756(1): 1-24).
  • Examples of the inorganic acid include hydrochloric acid, phosphoric acid, boric acid, metaphosphoric acid, pyrophosphoric acid, and sulfamic acid.
  • Examples of the inorganic acid salt include a dihydrogen phosphate salt (sodium salt, potassium salt, the same applies hereinafter), a mixture of a dihydrogen phosphate salt and a hydrogen phosphate salt, and the like.
  • One type of the pH adjuster may be used alone or two or more types may be used in combination.
  • the effective amount of the apoptosis inducing agent in the present invention ranges from 0.1 to 500 mg/kg of chlorine dioxide per day due to the size of the target tissue, and sometimes the area of the target tissue is more easily expressed.
  • the effective range of the apoptosis inducing agent in the invention is 0.1 to 500 mg of chlorine dioxide per 100 cm 2 per day, and is effective after at least 10 days when administered at the dose.
  • the chlorine dioxide preparation of the present invention has a very excellent cosmetic and skin care function as a cosmetic.
  • Water maze test continuous training for 3 days, 2 times / day before the experiment.
  • the square water labyrinth device is a black wooden trough 50cm ⁇ 30cm ⁇ 15cm, a starting zone, a 4-blind end meandering loop, and a safety platform.
  • the water depth is controlled at 12 cm and the water temperature is (25 ⁇ 2) °C.
  • the mouse is placed from the entrance end to start timing, and the number of times the blind end is touched is automatically recorded.
  • the mouse is climbed up to the safety station as the end time, which is called the incubation period.
  • the incubation period is set to a maximum of 120s, and animals that cannot be exported can be found after screening for more than 120s.
  • the chlorine dioxide preparation in an acidic environment can significantly improve the lifespan of the animal, accompanied by the improvement of memory and body capacity, the mechanism should be that the chlorine dioxide preparation can induce senescent cells. Apoptosis occurs and aging cells are cleared, and the body's own ability to regenerate will rejuvenate. Therefore, the chlorine dioxide preparation of the present invention can be used as a cosmetic for the skin rejuvenation, or can be made into a medicine for rejuvenating the body, thereby preventing the occurrence of senile diseases.
  • the chlorine dioxide preparation can effectively kill A549 cells, and their killing effect on A549 increases dose-dependently as the concentration increases, and the chlorine dioxide preparation results in half of the calculation by the SPSS software Probit module.
  • effective dose (IC 50) A549 cell death is 495ppm.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un inducteur d'apoptose cellulaire contenant du dioxyde de chlore. La présente invention concerne un nécessaire d'inducteur d'apoptose cellulaire contenant les deux constituants indépendants suivants : le premier constituant : un solide de précurseur de dioxyde de chlore ou une solution contenant un précurseur de dioxyde de chlore ; le second constituant : une solution aqueuse d'un agent d'ajustement d'acidité de pH ; les deux constituants sont stockés séparément et peuvent être mélangés avant leur utilisation, de telle façon qu'une réaction in situ se produit et l'inducteur d'apoptose cellulaire contenant du dioxyde de chlore est préparé ; les quantités et les concentrations du premier constituant et du second constituant permettent au pH de la solution mélangée d'être de 1,5 à 6.5. La présente invention concerne en outre l'utilisation de l'inducteur d'apoptose cellulaire contenant du dioxyde de chlore ou du nécessaire d'inducteur d'apoptose cellulaire contenant du dioxyde de chlore dans la préparation de médicaments pour traiter des tumeurs, ou son utilisation dans la préparation de médicaments anti-vieillissement pour des tissus cibles de mammifères, ou son utilisation comme produit cosmétique ou dans la préparation de médicaments chimiothérapeutiques.
PCT/CN2014/091047 2014-11-13 2014-11-13 Inducteur d'apoptose cellulaire contenant du dioxyde de chlore et son utilisation pour préparer des produits cosmétiques ou des médicaments anti-vieillissement ou anti-néoplasiques WO2016074203A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2014/091047 WO2016074203A1 (fr) 2014-11-13 2014-11-13 Inducteur d'apoptose cellulaire contenant du dioxyde de chlore et son utilisation pour préparer des produits cosmétiques ou des médicaments anti-vieillissement ou anti-néoplasiques

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2014/091047 WO2016074203A1 (fr) 2014-11-13 2014-11-13 Inducteur d'apoptose cellulaire contenant du dioxyde de chlore et son utilisation pour préparer des produits cosmétiques ou des médicaments anti-vieillissement ou anti-néoplasiques

Publications (1)

Publication Number Publication Date
WO2016074203A1 true WO2016074203A1 (fr) 2016-05-19

Family

ID=55953600

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2014/091047 WO2016074203A1 (fr) 2014-11-13 2014-11-13 Inducteur d'apoptose cellulaire contenant du dioxyde de chlore et son utilisation pour préparer des produits cosmétiques ou des médicaments anti-vieillissement ou anti-néoplasiques

Country Status (1)

Country Link
WO (1) WO2016074203A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103720709A (zh) * 2013-12-12 2014-04-16 刘学武 包含二氧化氯的细胞凋亡诱导剂及其在制备化妆品或抗衰老或抗肿瘤药物中的用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103720709A (zh) * 2013-12-12 2014-04-16 刘学武 包含二氧化氯的细胞凋亡诱导剂及其在制备化妆品或抗衰老或抗肿瘤药物中的用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIU, XUEWU;: "Essence of Aging-Model, Reason Anti-aging and Cancer", SCIENCEPAPER ONLINE, 27 January 2014 (2014-01-27), pages 8 *

Similar Documents

Publication Publication Date Title
KR102459500B1 (ko) 퀘르세틴 배당체를 함유하는 근위축 억제제
US20210077424A1 (en) Methods and use of inducing apoptosis in cancer cells
US20080020988A1 (en) Brain cell- or nerve cell-protecting agents comprising medicinal ginseng
US11524055B2 (en) Methods for treating diseases mediated by ERBB4-positive pro-inflammatory macrophages
JP7214268B2 (ja) 皮膚用組成物
CN103720709A (zh) 包含二氧化氯的细胞凋亡诱导剂及其在制备化妆品或抗衰老或抗肿瘤药物中的用途
CN105943530B (zh) 铁死亡抑制剂在制备治疗铁过载疾病的药物中的应用
MX2014004737A (es) Nueva sal y uso medico.
US20220249438A1 (en) Carbocyanine compounds for targeting mitochondria and eradicating cancer stem cells
US10933030B2 (en) Use of paeonol for inhibiting angiogenesis or for enhancing radiosensitization
KR102605627B1 (ko) 류신 유도체, 이를 포함하는 조성물 및 이의 용도
EP2585077B1 (fr) Agent inhibant la formation de cellules cutanées anormales induite par l'exposition à la lumière
JP2022504184A (ja) ブドウ膜黒色腫の治療のための併用療法
US20220110953A1 (en) Methods and compositions for treating human papillomavirus (hpv)-induced cancers
WO2016074203A1 (fr) Inducteur d'apoptose cellulaire contenant du dioxyde de chlore et son utilisation pour préparer des produits cosmétiques ou des médicaments anti-vieillissement ou anti-néoplasiques
CN112007039B (zh) 一种包含氟西汀和维生素d3或其衍生物的组合物，及其应用
US9540378B2 (en) Composition comprising purine derivatives or salt thereof for preventing or treating atopic dermatitis
BR112021001328A2 (pt) composições de licopeno e métodos para proteger a pele contra a radiação ultravioleta
KR20040074696A (ko) 항노화 활성이 우수한 현삼 추출물 및 이를 포함하는 조성물
CN110051671B (zh) 马齿苋酰胺e用于制备治疗缺血性心脏病的药物的用途
US20230277491A1 (en) Pharmaceutical combination comprising glycolic acid and l-alanine
WO2017035542A1 (fr) Compositions pharmaceutiques et procédés de traitement de maladies liées à l'hypoxie
JP6553961B2 (ja) 美白剤
TWI599353B (zh) 葉黃素用於治療癌症的用途
CN117045665A (zh) 毛蕊花糖苷的新用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14905817

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 25-09-2017)

122 Ep: pct application non-entry in european phase

Ref document number: 14905817

Country of ref document: EP

Kind code of ref document: A1